CORT Corcept Therapeutics
- 23.390
- +0.590+2.59%
Corcept Therapeutics News
Corcept Therapeutics Analyst Ratings
Analysts Are Bullish on These Healthcare Stocks: Corcept Therapeutics (CORT), Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Analysts Offer Insights on Healthcare Companies: Delcath Systems (DCTH), Zevra Therapeutics (ZVRA) and Corcept Therapeutics (CORT)
Truist Financial Gives a Buy Rating to Corcept Therapeutics (CORT)
Truist Securities Adjusts Price Target on Corcept Therapeutics to $42 From $36, Maintains Buy Rating
Analysts Are Bullish on Top Healthcare Stocks: Corcept Therapeutics (CORT), Bio-Rad Laboratories (BIO)
Analysts' Top Healthcare Picks: AngioDynamics (ANGO), Corcept Therapeutics (CORT)
Corcept Therapeutics: Hold Rating Amidst Generic Competition and Legal Challenges
Leerink Partners Keeps Their Hold Rating on Corcept Therapeutics (CORT)
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Incyte (INCY) and Nkarta (NKTX)
Analysts Offer Insights on Healthcare Companies: Paragon 28 (FNA), Intellia Therapeutics (NTLA) and Corcept Therapeutics (CORT)
Leerink Partners Keeps Their Hold Rating on Corcept Therapeutics (CORT)
HC Wainwright & Co. Maintains Buy on Corcept Therapeutics, Lowers Price Target to $28
Corcept Therapeutics Analyst Ratings
Balancing Near-term Risks With Long-term Potential: A Buy Rating for Corcept Therapeutics
Canaccord Genuity Maintains Buy on Corcept Therapeutics, Raises Price Target to $38
Corcept Therapeutics Analyst Ratings
Corcept Therapeutics (CORT) Gets a Buy From Piper Sandler
Truist Upgrades Corcept to Buy, Cites Market Potential for Relacorilant
Truist Securities Upgrades Corcept Therapeutics to Buy, Raises Price Target to $38
Analysis
Price Target
No Data
